Please share how you got the Pirenzepine....otherwise it is a teaser for those of us who would like relief. Thank you. I am grateful every day for this site and the sharing of information.
Results of the 2a study just published in one of the Lancet group publications. Jan 2026. Generally promising results.
eBioMedicine Home
Advanced search
ARTICLESVolume 123106055January 2026Open Access
Download Full Issue
Topical application of the antimuscarinic pirenzepine increased lower limb nerve fibre density in a phase 2a study in type 2 patients with diabetes with peripheral neuropathy
Ajith Sivadasana ∙ Paul Fernyhoughb,c ∙ Nigel A. Calcuttd ∙ Katie E. Frizzid,e ∙ Kimberly Gardnerd ∙ Angela Hansene ∙ et al.
Results of the 2a study just published in one of the Lancet group publications. Jan 2026. Generally promising results.
eBioMedicine Home
Advanced search
ARTICLESVolume 123106055January 2026Open Access
Download Full Issue
Topical application of the antimuscarinic pirenzepine increased lower limb nerve fibre density in a phase 2a study in type 2 patients with diabetes with peripheral neuropathy
Ajith Sivadasana ∙ Paul Fernyhoughb,c ∙ Nigel A. Calcuttd ∙ Katie E. Frizzid,e ∙ Kimberly Gardnerd ∙ Angela Hansene ∙ et al.
@proteusx - I thought I would share the link to the research article you posted so that other members can find it easier.
-- Topical application of the antimuscarinic pirenzepine increased lower limb nerve fibre density in a phase 2a study in type 2 patients with diabetes with peripheral neuropathy: https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(25)00499-2/fulltext
Thanks. And I would like to add that though WinSanTor's studies have focused primarily on diabetic peripheral neuropathy their researchers have indicated that the drug will likely also have benefits in several other forms of PN, including chemotherapy induced PN, though this remains to be demonstrated. At some point I will comment on my personal experience with "scrambler therapy" in Rome last summer and with my ongoing use of red light therapy and carboxy therapy.
I received some encouraging news from Winsantor this morning that it plans to make its pirenzepine drug available through the state of Montana's enlightened "Right to Try" legislation which allows use of not-yet FDA approved drugs by those suffering from severe debilitating diseases not satisfactorily treatable by other means. Winsantor recently published its Phase 2a clinical trial results in the highly respected journal Lancet, demonstrating both safety and efficacy. This is the first drug that shows the ability to actually modify the underlying causes of the disease rather than merely treat symptoms, such as pain, which the FDA, to the detriment of all of us, has chosen to prioritize for the last several decades. Winsantor has indicated that the drug may become available at state- designated Experimental Treatment Centers in Montana as early as this summer. Applicants will need statements from their physicians attesting to their neuropathic conditions and their resistance to other treatment modalities and, of course, they will need to provide informed consent. Patients will have to travel to Montana. Treatment costs will not be covered by insurance. Meanwhile, Winsantor will continue to pursue phase 3 studies, but these may take years to complete and. thanks to FDA's misplaced priorities. will prove highly costly.
I wander why there is no mention of releasing this drug in Canada before releasing it in the States? I mean lots of the research was done in Winnipeg and Toronto…. Comes down to money ultimately I suppose. I heard it could possibly be released earlier in Europe however. Anyone planning on going to Montana if it becomes available there?
I received some encouraging news from Winsantor this morning that it plans to make its pirenzepine drug available through the state of Montana's enlightened "Right to Try" legislation which allows use of not-yet FDA approved drugs by those suffering from severe debilitating diseases not satisfactorily treatable by other means. Winsantor recently published its Phase 2a clinical trial results in the highly respected journal Lancet, demonstrating both safety and efficacy. This is the first drug that shows the ability to actually modify the underlying causes of the disease rather than merely treat symptoms, such as pain, which the FDA, to the detriment of all of us, has chosen to prioritize for the last several decades. Winsantor has indicated that the drug may become available at state- designated Experimental Treatment Centers in Montana as early as this summer. Applicants will need statements from their physicians attesting to their neuropathic conditions and their resistance to other treatment modalities and, of course, they will need to provide informed consent. Patients will have to travel to Montana. Treatment costs will not be covered by insurance. Meanwhile, Winsantor will continue to pursue phase 3 studies, but these may take years to complete and. thanks to FDA's misplaced priorities. will prove highly costly.
Go to winsantor.com and click on Join Our Right To Try. I don't think they are taking people til this summer some time but you can get on their list so you will know when you can sign up.
Connect
Connect
Like
Helpful
Hug
Please share how you got the Pirenzepine....otherwise it is a teaser for those of us who would like relief. Thank you. I am grateful every day for this site and the sharing of information.
-
Like -
Helpful -
Hug
2 ReactionsResults of the 2a study just published in one of the Lancet group publications. Jan 2026. Generally promising results.
eBioMedicine Home
Advanced search
ARTICLESVolume 123106055January 2026Open Access
Download Full Issue
Topical application of the antimuscarinic pirenzepine increased lower limb nerve fibre density in a phase 2a study in type 2 patients with diabetes with peripheral neuropathy
Ajith Sivadasana ∙ Paul Fernyhoughb,c ∙ Nigel A. Calcuttd ∙ Katie E. Frizzid,e ∙ Kimberly Gardnerd ∙ Angela Hansene ∙ et al.
-
Like -
Helpful -
Hug
1 Reaction@proteusx - I thought I would share the link to the research article you posted so that other members can find it easier.
-- Topical application of the antimuscarinic pirenzepine increased lower limb nerve fibre density in a phase 2a study in type 2 patients with diabetes with peripheral neuropathy:
https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(25)00499-2/fulltext
-
Like -
Helpful -
Hug
1 ReactionThanks. And I would like to add that though WinSanTor's studies have focused primarily on diabetic peripheral neuropathy their researchers have indicated that the drug will likely also have benefits in several other forms of PN, including chemotherapy induced PN, though this remains to be demonstrated. At some point I will comment on my personal experience with "scrambler therapy" in Rome last summer and with my ongoing use of red light therapy and carboxy therapy.
-
Like -
Helpful -
Hug
1 ReactionI received some encouraging news from Winsantor this morning that it plans to make its pirenzepine drug available through the state of Montana's enlightened "Right to Try" legislation which allows use of not-yet FDA approved drugs by those suffering from severe debilitating diseases not satisfactorily treatable by other means. Winsantor recently published its Phase 2a clinical trial results in the highly respected journal Lancet, demonstrating both safety and efficacy. This is the first drug that shows the ability to actually modify the underlying causes of the disease rather than merely treat symptoms, such as pain, which the FDA, to the detriment of all of us, has chosen to prioritize for the last several decades. Winsantor has indicated that the drug may become available at state- designated Experimental Treatment Centers in Montana as early as this summer. Applicants will need statements from their physicians attesting to their neuropathic conditions and their resistance to other treatment modalities and, of course, they will need to provide informed consent. Patients will have to travel to Montana. Treatment costs will not be covered by insurance. Meanwhile, Winsantor will continue to pursue phase 3 studies, but these may take years to complete and. thanks to FDA's misplaced priorities. will prove highly costly.
-
Like -
Helpful -
Hug
1 ReactionI wander why there is no mention of releasing this drug in Canada before releasing it in the States? I mean lots of the research was done in Winnipeg and Toronto…. Comes down to money ultimately I suppose. I heard it could possibly be released earlier in Europe however. Anyone planning on going to Montana if it becomes available there?
@proteusx I would love to volunteer for the project.
Godspeed to this project.
Go to winsantor.com and click on Join Our Right To Try. I don't think they are taking people til this summer some time but you can get on their list so you will know when you can sign up.